Coronary artery disease and post-PCI care
Research activity is centered on patients with stable or unstable coronary syndromes after successful percutaneous coronary intervention, with attention to long-term treatment choices in this setting.
- Coronary syndromes
- Post-PCI antithrombotic management
- Ischaemic risk reduction
The sponsor’s funded research reflects a clinical interest in optimizing secondary prevention for patients recovering from coronary revascularisation.
Antiplatelet therapy strategies
The trial portfolio focuses on comparing single antiplatelet therapy and dual antiplatelet therapy in the context of coronary disease, with emphasis on balancing protection from thrombotic events and treatment-related harm.
- Single antiplatelet therapy
- Dual antiplatelet therapy
- Thrombotic event prevention
Interest extends to treatment selection in older patients and in those with heightened vulnerability to adverse effects from intensified antithrombotic treatment.
Bleeding risk and clinical safety
A major therapeutic focus is the reduction of bleeding complications while maintaining cardiovascular protection, particularly in patients at increased risk of haemorrhagic events.
- Clinically relevant bleeding
- High bleeding risk patients
- Net clinical benefit
The funded research examines safety outcomes alongside cardiovascular efficacy, reflecting an interest in treatment regimens that are better suited to fragile patient groups.
Cardiovascular outcomes and event prevention
Clinical outcomes of interest include major adverse cardiovascular events and composite measures that capture both ischaemic and bleeding endpoints, supporting a broad assessment of patient benefit after coronary intervention.
- Major adverse cardiovascular events
- Composite clinical outcomes
- Secondary prevention
This area of research aligns with efforts to refine antithrombotic care for older adults and other patients in whom treatment intensity must be carefully matched to risk.
